The company, which is based in Martinsried, Germany, is a developer of sample preparation tools and consumables for proteomics analysis by mass spectrometry. It was founded in 2016 by Garwin Pichler, PhD, and Nils Kulak, PhD, as a spinout company from the laboratory of proteomics researcher professor Matthias Mann at the Max Planck Institute of Biochemistry in Martinsried.

PreOmics' sample processing technologies for mass spectrometry-based protein analysis are complementary to Bruker's scientific instruments, as well as to proteomics mass spectrometry systems produced by other proteomics companies.

Close collaboration synergies are expected to broaden market opportunities for both PreOmics' BeatBox platform technologies and Bruker's timsTOF 4D proteomics platform, with more complete automated workflow solutions for academic and clinical researchers, biomarker discovery and diagnostics companies, as well as for contract research organizations and biopharmaceutical companies, PreOmics said.

In conjunction with the series B financing, several early investors in PreOmics, including High-Tech Gründerfonds, Think.Health Ventures, and certain angel investors, have sold their PreOmics shares to Bruker in a parallel secondary transaction. Bruker is now a majority investor in PreOmics. Financial details of the secondary transactions were not disclosed.

BeatBox by PreOmics for high-throughput tissue and cell homogenization. Image courtesy of PreOmics.